Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immunotherapy duo takes on rare, tough ovarian cancer

NCT ID NCT03355976

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 30 times

Summary

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink tumors in people with advanced clear cell carcinoma of the ovary, fallopian tube, peritoneum, or other organs. About 46 participants with recurrent or metastatic disease will receive one of the two treatments. The goal is to see if these drugs can help control the cancer by boosting the immune system to attack tumor cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

  • The Miriam Hospital

    Providence, Rhode Island, 02906, United States

  • University of Illinois Chicago

    Chicago, Illinois, 60612, United States

  • Women & Infants Hospital

    Providence, Rhode Island, 02905, United States

Conditions

Explore the condition pages connected to this study.